Atlas Legacy Advisors LLC Takes Position in Stryker Co. (NYSE:SYK)

Atlas Legacy Advisors LLC purchased a new stake in Stryker Co. (NYSE:SYK) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 2,158 shares of the medical technology company’s stock, valued at approximately $777,000.

A number of other hedge funds also recently made changes to their positions in SYK. Dunhill Financial LLC boosted its stake in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at approximately $36,000. Activest Wealth Management acquired a new stake in shares of Stryker in the 4th quarter valued at approximately $36,000. Crews Bank & Trust acquired a new stake in shares of Stryker in the 4th quarter valued at approximately $39,000. Finally, Hara Capital LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at approximately $42,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.50% of the company’s stock.

Stryker Stock Up 0.1 %

Stryker stock opened at $385.44 on Wednesday. The firm has a market cap of $147.08 billion, a price-to-earnings ratio of 49.67, a PEG ratio of 2.90 and a beta of 0.96. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a 50 day moving average price of $377.44 and a two-hundred day moving average price of $367.94.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business posted $3.46 earnings per share. Equities analysts predict that Stryker Co. will post 13.49 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is 43.30%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Royal Bank of Canada raised their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. JPMorgan Chase & Co. raised their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday. Finally, UBS Group raised their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $420.68.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.